Implications of imatinib mesylate for hematopoietic stem cell transplantation
- 1 July 2001
- journal article
- Published by Elsevier in Seminars in Hematology
- Vol. 38, 28-34
- https://doi.org/10.1016/s0037-1963(01)90115-5
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Cytomegalovirus seropositivity adversely influences outcome after T‐depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft‐versus‐host disease prophylaxisBritish Journal of Haematology, 2001
- Chronic Myelogenous Leukemia: Biology and TherapyAnnals of Internal Medicine, 1999
- Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantationThe Lancet, 1998
- Bone Marrow Transplants from Unrelated Donors for Patients with Chronic Myeloid LeukemiaNew England Journal of Medicine, 1998
- Chronic myeloid leukemiaCurrent Opinion in Hematology, 1998
- Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor ProgramBlood, 1993
- Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patientsBlood, 1990
- MARROW TRANSPLANTATION FOR PATIENTS IN THE CHRONIC PHASE OF CHRONIC GRANULOCYTIC LEUKAEMIAThe Lancet, 1982
- TREATMENT OF CHRONIC GRANULOCYTIC LEUKAEMIA IN CHRONIC PHASE BY ALLOGENEIC MARROW TRANSPLANTATIONThe Lancet, 1982
- Disappearance of pH1-Positive Cells in Four Patients with Chronic Granulocytic Leukemia after Chemotherapy, Irradiation and Marrow Transplantation from an Identical TwinNew England Journal of Medicine, 1979